文献速递急性肾损伤肾小球疾病遗传性与小管间质肾病

补体C3 p.Arg161Trp变异相关非典型溶血性尿毒症综合征的临床表型

Atypical Hemolytic Uremic Syndrome in Children and Adults With the Hot Spot C3 Gene Variant p.Arg161Trp.
PubMed 文献 · Kidney Int Rep · 2026-05-16

本研究回顾性纳入37例携带C3 p.Arg161Trp变异的荷兰补体介导非典型溶血性尿毒症综合征患者(11例儿童,26例成人),描述其临床表型。儿童起病时溶血更重但急性肾损伤较轻,成人更易进展至终末期肾病;儿童和成人复发率分别达82%和86%。

要点

  • 儿童起病溶血更重(血小板更低、LDH更高),但肾功能损伤较轻。
  • 成人起病肾功能更差,1年内11/26例进展至终末期肾病。
  • 携带该变异者复发风险高,儿童和成人复发率分别达82%和86%。

核心结论

  • C3 p.Arg161Trp相关补体介导非典型溶血性尿毒症综合征临床异质性显著,儿童与成人表现及结局不同。
  • 儿童表现为更严重的溶血但较轻的急性肾损伤,且该变异与高复发风险相关。

研究设计与样本

  • 回顾性观察性研究,纳入2023年10月前识别的37例荷兰C3 p.Arg161Trp变异相关补体介导非典型溶血性尿毒症综合征患者(11例儿童,26例成人)。

主要发现

  • 儿童与成人起病时血小板计数分别为21 vs. 79 x 109/L(P = 0.036),乳酸脱氢酶分别为2644 vs. 1260 U/L(P = 0.026)。
  • 儿童与成人起病时eGFR分别为48 vs. 15 ml/min per 1.73 m2(P < 0.001),红色尿比例90 vs. 24%(P = 0.001),黄疸比例50 vs. 10%(P = 0.022)。
  • 儿童起病后1年内无一例进展至终末期肾病,成人26例中11例进展。
  • 儿童中10例初始完全恢复,其中1例接受eculizumab治疗;成人中接受eculizumab治疗者肾功能恢复比例88%(n = 7/8),未接受者为44%(n = 8/18)。
  • 儿童和成人自体肾脏复发率分别为82%和86%,起病至复发中位(范围)时间1.9(0.3-17.6)年。

临床怎么用

  • 对携带C3 p.Arg161Trp变异的补体介导非典型溶血性尿毒症综合征患者,儿童与成人需分别评估溶血和肾功能损害。
  • 成人患者应尽早考虑eculizumab治疗以促进肾功能恢复。
  • 儿童和成人均需长期监测复发,因复发率高达82%和86%。

局限性

  • 回顾性观察性研究,样本量37例,部分患者起病于eculizumab可及前。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The gain-of-function variant C3 p.Arg161Trp is found in a quarter of Dutch patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS). In this study, we describe the clinical phenotype of C3 p.Arg161Trp-associated CaHUS. METHODS: Dutch patients with CaHUS with the C3 p.Arg161Trp variant, identified before October 2023, were included in this retrospective, observational study. RESULTS: A total of 37 patients (11 children and 26 adults) were included, with onset before and after availability of eculizumab. Presentation at onset differed between children and adults, specifically in platelet count (21 vs. 79 x 109/L, P = 0.036), lactate dehydrogenase (2644 vs. 1260 U/L, P = 0.026), estimated glomerular filtration rate (eGFR) (48 vs. 15 ml/min per 1.73 m2, P < 0.001), red-colored urine (90 vs. 24%, P = 0.001), and jaundice (50 vs. 10%, P = 0.022). None of the children developed end-stage kidney disease (ESKD) within a year after disease onset, in contrast to 11 of 26 adults. Ten children initially showed full recovery, of which 1 had received eculizumab. In adults, kidney function recovery occurred more often in those treated with eculizumab (88%, n = 7/8), compared with adults not treated with eculizumab (44%, n = 8/18). Relapse rate in the native kidneys of children and adults was high, 82% and 86%, respectively. The median (range) time between disease onset and relapse was 1.9 (0.3-17.6) years. CONCLUSION: The clinical phenotype of C3 p.Arg161Trp-associated CaHUS has significant heterogeneity, with differences in presentation and outcomes between children and adults. Children present with more profound hemolysis but milder acute kidney injury (AKI). Furthermore, C3 p.Arg161Trp is linked to a high risk of relapse.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ter Steeg L, Bouwmeester RN, Ter Avest M, et al. Atypical Hemolytic Uremic Syndrome in Children and Adults With the Hot Spot C3 Gene Variant p.Arg161Trp. Kidney Int Rep. 2026. PMID: 42318533. doi:10.1016/j.ekir.2026.106599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。